Biosimilars
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.
Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion
Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition
Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset
Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology
Coherus Biosciences Addresses Temporary UDENYCA Supply Interruption
UDENYCA, Coherus Biosciences, supply interruption, biosimilar, pegfilgrastim, Neulasta, cancer treatment, white blood cell count, pharmaceutical supply chain.
Regeneron Takes Legal Action Against Sandoz to Block Eylea Biosimilar
Regeneron, Sandoz, Eylea, biosimilar, lawsuit, patent infringement
Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars
Cigna, Express Scripts, Humira, biosimilars, drug pricing, pharmaceutical industry
FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan
biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
Samsung Bioepis Sees 107% Sales Growth in Q2, Driven by Biosimilars
Samsung Bioepis, biosimilars, sales growth, Q2, operating profit, market share
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions